Reporting from the ESMO Virtual Congress 2020, Sandro Pignata features results from the ovarian cancer studies performed in the advanced setting, IMagyn050/GOG 3015/ENGOT-OV39 which explored a combination of bevacizumab with immune checkpoint inhibitor atezolizumab, and PAOLA-1 about maintenance treatment with a combination of olaparib and bevacizumab that confirmed the important role of PARP inhibitors in the management of ovarian cancer.
He also discusses the results from the INOVATYON trial looking at the effect of platinum-based therapy free intervals in the treatment of recurrent disease.
Abstracts:
- LBA31 - Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo-controlled randomised phase 3 trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)
- LBA33 - Final second progression-free survival (PFS2) with maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer (HGOC) in the Phase III PAOLA-1 trial
- LBA30 - INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs a platinum-based regimen in patients with recurrent ovarian cancer (ROC) progressing within 6-12 months after last platinum line.
This video was supported with a grant from Bayer Healthcare and Roche